Evidence map›Paper›PMID 38660533›Full record

ArticleRSC advances2024

Inhibition of survivin by 2'-

Yalin Li, Suxiang Chen, Kamal Rahimizadeh, Zhen Zhang, Rakesh N Veedu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RSC advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Molecularly targeted therapy and immunotherapy in leukemias.Journal of hematology & oncology · 2026
    Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Yalin LiSchool of Food and Biological Engineering, Henan University of Animal Husbandry and Economy Zhengzhou 450018 China.
Suxiang ChenCentre for Molecular Medicine and Innovative Therapeutics, Health Futures Institute, Murdoch University Murdoch 6150 Australia Suxiang.Chen@murdoch.edu.au R.Veedu@murdoch.edu.au.
Kamal RahimizadehCentre for Molecular Medicine and Innovative Therapeutics, Health Futures Institute, Murdoch University Murdoch 6150 Australia Suxiang.Chen@murdoch.edu.au R.Veedu@murdoch.edu.au.
Zhen ZhangSchool of Food and Biological Engineering, Henan University of Animal Husbandry and Economy Zhengzhou 450018 China.
Rakesh N VeeduCentre for Molecular Medicine and Innovative Therapeutics, Health Futures Institute, Murdoch University Murdoch 6150 Australia Suxiang.Chen@murdoch.edu.au R.Veedu@murdoch.edu.au.ORCID https://orcid.org/0000-0003-2192-9532
Murdoch University · AUHenan University of Economic and Law · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chemically modified antisense oligonucleotide (ASO) has been established as a successful therapeutic strategy for treating various human diseases. To date, ten ASO drugs, which are capable of either inducing mRNA degradation

Identifiers

PMID38660533
PMCPMC11040434
OpenAlexW4395075633

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.